BEST-RPP Pilot: Screening for Esophageal Cancer in Rural Oregon Without an Endoscopy - Trial NCT06335966
Access comprehensive clinical trial information for NCT06335966 through Pure Global AI's free database. This phase not specified trial is sponsored by OHSU Knight Cancer Institute and is currently Recruiting. The study focuses on Esophageal Cancer. Target enrollment is 110 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Screening with swallowable esophageal cell-collection devices (SECD)
Observational
device
Sponsor & Location
OHSU Knight Cancer Institute
Timeline & Enrollment
N/A
Jan 25, 2024
Jan 30, 2025
Primary Outcome
Feasibility of the use of a SECD: Number of providers who indicate likelihood of using SECD,Feasibility of the use of SECD: Number of providers who indicate willingness to be trained and train clinic staff,Feasibility of the use of SECD: Number of referrals,Feasibility of the use of SECD: Number enrolled,Patient acceptability: Number of interested patients who schedule an appointment to be screened,Patient acceptability: Number of patients who come to their appointments,Patient acceptability: Number of patients interested in being screened via SECD at other care centers
Summary
Recent advancements in swallowable esophageal cell-collection devices (SECD) offer a safe,
 minimally invasive, accurate, and low-cost alternative to esophageal screening without the
 need for an upper endoscopy. The BEST-RPP study aims to evaluate the acceptability and
 feasibility of using this novel approach to screen for Barrett's Esophagus (BE) and
 Esophageal Carcinoma (EAC) in rural primary care clinic settings in Oregon.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06335966
Device Trial